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Abstract
Fibrous Dysplasia / McCune Albright syndrome (FD/MAS) represents a wide spectrum of diseases due to somatic
gain-of-function mutations of the GNAS gene. The mutation leads to overactivity in the target tissues and to a wide
phenotype of clinical features that vary in severity and age of onset. The rarity of the disease and its variable
presentation to multiple specialities often leads to misdiagnosis and inappropriate variability in investigations and
treatments. To address this, our international consortium of clinicians, researchers, and patients’ advocates has
developed pragmatic clinical guidelines for best clinical practice for the definition, diagnosis, staging, treatment and
monitoring for FD/MAS to empower patients and support clinical teams in both general and specialised healthcare
settings. With the lack of strong evidence to inform care, the guidelines were developed based on review of
published literature, long-standing extensive experience of authors, input from other healthcare professionals
involved in the care of FD/MAS patients and feedback from patients and patient groups across the globe. This has
led to the formulation of a set of statements to inform healthcare professionals, patients, their families, carers and
patient groups of the best practice of care. It is anticipated the implementation of these recommendations will lead
to improvement in the care of patients with FD/MAS internationally.
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Background
Fibrous dysplasia/McCune-Albright syndrome (FD/
MAS; OMIM#174800) is a rare disorder characterized
by skeletal lesions, skin hyperpigmentation, and hyper-
functioning endocrinopathies [1, 2]. It arises from post-
zygotic gain-of-function mutations in the GNAS gene,
which encodes the α-subunit of the Gs signalling protein
[3]. These mutations disrupt the intrinsic GTPase activ-
ity of Gsα, leading to persistent stimulation of adenylyl
cyclase and dysregulated production of cyclic AMP and
downstream signalling [4]. The resulting disease is mo-
saic with a broad clinical spectrum, ranging from a triv-
ial incidentally discovered radiographic finding to severe
and disabling disease. FD may involve one (monostotic)
or multiple (polyostotic) bones and may occur in isola-
tion or in combination with extraskeletal disease [5].
While FD/MAS is classically defined as involving the
skeleton, skin, and endocrine systems, given the ubiqui-
tous nature of Gs signalling, multiple other tissues may
also be affected. Any part or combination of features
may be present.
Clinical management in FD/MAS is challenging, and
multiple barriers exist to providing consistent, high quality
care. Some of these include the broad clinical spectrum
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which results in considerable phenotypic variability among
patients; multisystem involvement which requires coordin-
ation between diverse specialties; and disease rarity, which
makes it challenging for individual clinicians and centres to
gain specialist expertise in the disorder’s ubiquitous mani-
festations. There is little high-quality evidence to inform
the diagnosis and management of FD/MAS. There are as
yet substantial knowledge gaps about FD/MAS pathophysi-
ology and natural history, and a paucity of hard evidence
from clinical trials for different diagnostics and therapeutic
approaches. To address these challenges, an international
consortium of clinicians, researchers, and patients’ advo-
cates convened to develop standard of care guidelines for
diagnosis and management of FD/MAS based on best avail-
able evidence and expert opinion [6].
The aim of developing best clinical practice care guidelines
for diagnosis and management of FD/MAS is to harmonize
the care of FD/MAS internationally, to provide standards of
care for the development and evaluation of patient-related
outcome measures, to provide a uniform cross-border
standard of care for inclusion of patients into clinical trials,
and to enable comparison of collected clinical care and re-
search FD/MAS data between centres and studies.
Methods
These guidelines were co-developed by clinical experts
in the management of FD/MAS from the FD/MAS con-
sortium and patient advocacy groups [6]. The FD/MAS
Consortium consisted of 51 FD/MAS clinical and pa-
tient experts from 13 countries from Europe, the United
States of America and Asia. The Guideline Development
Group (GDG) consisted of a subgroup of experts from
paediatric and adult rheumatology, endocrinology, or-
thopaedics, maxillofacial surgery, radiology, dentistry, a
pain specialist and expert representatives form national
FD/MAS patient groups. The GDG was formed at a con-
sensus meeting held in Oxford in October 2015 [6]. This
first meeting identified key questions for the development
of clinical care guidelines and a modified Delphi approach
was selected to address these questions. The GDG
reviewed the past 30 years’ published evidence using the
MeSH term “Fibrous Dysplasia of Bone” on Medline.
Given the rarity of FD/MAS there are very few published
randomised control trials, and marked heterogeneity in
case definitions, interventions and outcomes used. The
GDG therefore used the best of the existing data together
with personal expertise and experience in FD/MAS.
The GDG developed a first draft of the clinical care
pathway that was circulated to the broader membership of
the Consortium for comment. The responses were
reviewed at the second consensus meeting of the FD/
MAS Consortium in Lyon in December 2016. The con-
sensus draft of the clinical care pathways was recirculated
to members of the international consortium for final
comments. The comments and suggestions for the clinical
pathway were then reviewed by the writing group and for-
mulated statements with over 70% consensus were included
in the final report. The patient group representatives then
independently developed a separate patient checklist to give
context to the clinical pathway, including questions patients
may want to ask their doctor and questions their doctor
may ask them.
The writing group chose to submit the guidelines for
publication in an open access journal in order to make it
freely accessible to a wide readership of clinicians, basic
scientists and patients, also using the creative commons
licence on patient group websites. The Consortium will
review the guidelines at least every 5 years or sooner if
required by breakthrough findings from published litera-
ture. The guidelines were developed without external fi-
nancial support from industries involved in therapies for
FD/MAS. Competing interests of members were re-
corded and documented in the pathway.
Definition
A diagnosis of the subtypes of FD/MAS can only be made
after a thorough evaluation of a) the extent of skeletal dis-
ease: monostotic/polyostotic and b) the presence of extra-
skeletal manifestations. Monostotic fibrous dysplasia is de-
fined as the presence of fibrous dysplasia in one skeletal
site only. Polyostotic fibrous dysplasia is defined as the
presence of fibrous dysplasia in more than one skeletal site
without extra-skeletal manifestations. McCune-Albright
syndrome is defined as the combination of FD and one or
more extra skeletal feature, OR the presence of two or
more extra skeletal features. Not requiring FD for the
diagnosis of MAS reflects better understanding of the mo-
lecular pathogenesis of the disorder. Mazabraud Syn-
drome is the combination of FD with intramuscular
myxoma(s). The myxoma is defined as an extra-skeletal
manifestation of FD/MAS and may occur in association
with any type of the disease (monostotic, polyostotic or
MAS). Other extra-skeletal features include:
1. Café-au-lait skin macules with characteristic
features of jagged, irregular borders (Coast of
Maine) and a distribution showing the so-called “re-
spect of” the midline of the body (Fig. 1);
2. Gonadotropin-independent sex steroid production
resulting in precocious puberty, recurrent ovarian
cysts in girls (Fig. 2a) and women or autonomous
testosterone production in boys and men (Fig. 2b).
This includes testicular lesions consistent with FD/
MAS with or without associated gonadotropin-
independent precocious puberty.
3. Thyroid lesions consistent with FD/MAS with or
without non-autoimmune hyperthyroidism (Fig. 2c)
4. Growth hormone excess (Fig. 2d)
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Fig. 1 Representative images of café-au-lait macules in patients with McCune-Albright syndrome. Photographs of the shoulder (a), back (b), and
legs (c) from three patients demonstrating characteristic hyperpigmented lesions with jagged borders, and tendency to either occur or reflect
around (“respect”) the midline of the body. Images A and C show large lesions, while the patient in image B has two small lesions in a classic
location, demonstrating the broad potential spectrum of involvement
Fig. 2 Representative radiographic features of endocrine involvement in McCune-Albright syndrome. a Pelvic ultrasonography in a 5-year-old girl
with clinical signs of precocious puberty demonstrating a large unilateral ovarian cyst. b Testicular ultrasonography in a patient with macro-
orchidism demonstrating a discrete, mixed hyper- and hypoechoic lesion (red arrowheads). c Thyroid ultrasonography showing diffuse, bilateral
involvement with multiple hyper- and hypoechoic nodules. d A pituitary MRI in a patient with growth hormone excess revealing a pituitary
macroadenoma (red arrow) and fibrous dysplasia involvement throughout the skull base (white star)
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5. Neonatal hypercortisolism
Of note, FGF-23-associated hypophophataemia is not
considered a feature of MAS but rather a marker of the
severity of skeletal FD.
Diagnosis
In most cases, the diagnosis of FD/MAS can be made
clinically after a complete staging evaluation for skeletal,
endocrine, soft tissue and dermatologic features [7, 8].
Isolated monostotic bone lesions without accompanying
skin or endocrine findings include a wide differential
diagnosis and diagnostic uncertainty and usually require
histological confirmation (Table 1). In some cases a mo-
lecular diagnosis of affected tissues is indicated when
clinical, radiological and histological analysis fails to con-
firm the diagnosis of FD.
Radiological characterisation
A number of radiological techniques are recommended for
the diagnosis of FD/MAS and specialist radiological expert-
ise is required to differentiate FD/MAS from other mimics.
General radiologic features of FD/MAS on conventional
radiography include: ground-glass appearance; completely
radiolucent (cystic) lesions, sclerotic lesions or mixed cys-
tic and sclerotic lesions; well-circumscribed margins (geo-
graphic pattern), with or without a sclerotic border; and
expanded lesions with a shell that is thick, thin, or
showing small perforations and/or endosteal scalloping
[9]. A soft tissue mass is not a radiological feature of FD
and should be further investigated (Fig. 3a–e). The specific
radiological features of FD are described in Table 2.
CT is useful for assessing regions with complex anat-
omy of skeletal structure e.g. face, pelvis, spine, and for
detecting subtle un-displaced fractures. The presence of
extra-osseous soft tissue mass with bony destruction
would suggest malignant transformation. Although FD
has non-specific features on MRI, this imaging tool al-
lows differentiation of FD from a cyst lesion. The le-
sion(s) may contain fluid/fluid levels but there should
not be a soft tissue mass. Lesions are patchy with low to
intermediate signalling on T1 and T2-weighted images
and may show high signalling on T2-weighted images in
children. Inversion recovery pulse sequences give a high
signal and there is patchy contrast enhancement.
Nuclear medicine imaging studies such as 99mTc-MDP,
usually combined with single-photon emission com-
puted tomography (SPECT) to give better anatomical
resolution, or 18F NaF PET/CT demonstrate increased
tracer uptake at the foci of skeletal disease [10].
Histological and genetic characterisation
Biopsy with histological evaluation of suspected bone dis-
ease is usually only necessary in unusual or questionable
cases, and/or if malignancy is suspected. The risks and
benefits of a biopsy should be clearly explained to patients,
Table 1 Potential mimics of fibrous dysplasia by skeletal site
Site Differential diagnosis
General Cancer (primary or secondary) or hematologic malignancy including solitary plasmocytoma sarcoma
Enchondromatosis
Simple bone cyst (unicameral)
Giant cell tumours
Aneurysmal bone cyst
Paget’s disease of bone
Neurofibromatosis type I
Cutaneous Skeletal Hypophosphatemia syndrome
Langerhans cell Histiocytosis
Melorrheostosis
Osteonecrosis
Osteitis Fibrosa Cystica (Recklinghausen)
Craniofacial bones Ossifying fibroma
Fibro-osseous lesion
Cherubism
Aseptic mandibular osteitis (SAPHO syndrome)
Central giant-cell granuloma
Fronto-sphenoidal Meningioma
Tibia Adamantinoma and osteofibrous dysplasia
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including that a biopsy does not typically lead to regrowth
of FD.
The benefit of genetic testing in patients with a clear
clinical diagnosis is uncertain. A genetic diagnosis is rec-
ommended where the diagnosis is in question. This es-
pecially applies to isolated/monostotic lesions in the
skull, after exclusion of other associated skeletal and/or
extraskeletal features- e.g. other bones / skin features/
endocrinopathies. Diagnostic biopsies should be proc-
essed as fresh or fresh frozen material to enable genetic
testing for GNAS mutation. False negatives may occur if
the biopsy contains normal tissue and the biopsy may
Fig. 3 Representative radiographic features of fibrous dysplasia. a Femoral X-ray demonstrating diffuse involvement with fibrous dysplasia and a
coxa vara (“shepherd’s crook”) deformity (red arrow). Note the irregular appearance of the distal femoral metaphyses (yellow arrowhead) resulting
from FGF-23-mediated rickets. b Humeral X-ray demonstrating characteristic features of fibrous dysplasia, including homogenous “ground glass”
appearance and cortical thinning. Bowing has occurred at a previously fractured site in the midshaft (red arrowhead). c X-ray from a patient with
diffuse spinal FD and resulting thoraco-lumbar scoliosis. Note the presence of bilateral intramedullary femoral rods. d Technetium-99 scintigraphy
scan showing increased tracer uptake in areas of fibrous dysplasia, including the skull, spine, right humerus, and right lower extremity (red
arrowheads). Diffuse bilateral tracer uptake is also observed in the epiphyses of this growing adolescent. e T2-weight magnetic resonance
imaging of the lower extremities showing well-demarcated lesions of intermediate to high signal intensity in the bilateral femurs (red arrows),
corresponding to fibrous dysplasia lesions. f Computed tomography of the skull showing diffuse homogenous, “ground glass” involvement
characteristic of craniofacial fibrous dysplasia. The bilateral optic canals are involved with fibrous dysplasia and widely patent (red arrows)
Table 2 Specific radiological features dependent on body site [10]
Bone Features
Pelvis and ribs • Fibrous dysplasia is the most common cause of a benign expansile lesion of a rib.
• Expansile lytic lesion
• Fusiform enlargement of the rib
• Minor calcifications within the lesion may be seen
Extremities • Bowing deformity, in particular of the large weight-bearing bones (e.g. shepherds crook deformity of the proximal
• femur)
• Looser zones
• Co-existent precocious puberty may lead to premature fusion of growth plates resulting in short stature
Skull and craniofacial bones • Bone expansion showing ground-glass appearance
• Calvarial deformity resulting in exophthalmos
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need to be repeated. Mutation analysis can also be per-
formed in paraffin-embedded samples although false
negatives are then more likely [11]. Next generation se-
quencing (NGS) has a lower false negative outcome than
Sanger sequencing. False positives have not been described
using NGS and this sequencing technique can be used to
differentiate FD/MAS from osteosarcomas [12]. Use of
blood for mutation analysis cannot exclude the diagnosis
of monostotic FD, but a positive result is informative.
Staging of FD/MAS
The purpose of staging of FD/MAS is to determine the
full extent and impact of disease at diagnosis to guide
tests and treatments and to minimize risk of complica-
tions. Staging should be considered at the time of pres-
entation with suspected FD/MAS taking into account
age and clinical presentation. The key components of
staging are listed below.
Evaluation of the skeletal system
(See Additional file 2: Flow chart: Skeletal evaluation
FD lesion(s))
Assessment of the skeletal system requires a full medical
history, physical examination, laboratory investigations
and radiological and nuclear imaging. Assessment of skel-
etal symptoms should include a skeletal map with areas
marked for bone pain (see below), joint pain and bone/
joint deformity; a fracture history including site, date, level
of trauma (e.g. spontaneous, fragility, severe trauma) and
fracture healing (complete / incomplete / non-healing);
previous orthopaedic procedures (type and date) including
details of metalwork insertion (location and type). The fol-
lowing information should be collected on previous use of
bone specific therapy: ever use, generic name of drug, date
of first and last use and total number of years of use. Pre-
vious or current participation in clinical trials should be
recorded and include the date of the trial(s) and treat-
ment(s) tested should be documented.
Assessment of severity of pain should include a VAS
0–10 and Brief Pain Inventory [13] for adults or Wong
Baker Facies [14] for children. The presence of night
pain should raise a red flag for possible complications
such as imminent fracture, bleeding into a cyst or very
rarely malignant transformation. A potential neuropathic
character to pain should be assessed using the PainDe-
tect questionnaire [15]. The contribution of pain from
surgical scars, referred pain from adjacent joints, local
tendinosis, chronic pain disorders/ fibromyalgia should
also be evaluated.
In the presence of focal and/or acute onset pain, acute
or impending fracture, aneurysmal bone cyst or stress
fracture especially in a deformed long bone should be
considered. Mechanical pain can be provoked using the
rotational stress test, for instance in lesions of the
proximal femur. The FABER test: motion hip in Flexion,
ABduction and External Rotation, is also recommended.
Although very rare, sarcomatous change should be con-
sidered in the presence of diffuse and/or chronic pain,
especially if progressive and unrelenting and also present
at night. This should be further evaluated using CT/ MR
imaging and discussed with the local sarcoma team.
Mechanical/ weight bearing bone pain can signal a stress
or impending fracture. This should trigger consideration
for correction of alignment, and/or consideration for the
necessity of a surgical procedure, possibly involving the
use of an intramedullary titanium nail or custom-made
titanium angled blade plate, based on the ‘bridging the
defect’ principles, to stabilize the involved bone.
Physical examination of the skeletal system should in-
clude gait, deformity including leg length discrepancy to
inform potential complications, areas of tenderness and
range of movement of adjacent joints and presence of
spinal kyphosis and scoliosis [16–18].
Bone-related laboratory testing [19–22] should include
a standard biochemistry screen of renal profile, total
alkaline phosphatase, bicarbonate, albumin-adjusted
serum calcium, phosphate (see below), 25OH-vitamin D
and parathyroid hormone.
Abnormal phosphate homeostasis, specifically renal
phosphate wasting leading to hypophosphatemia, is import-
ant to diagnose as it is an important predictor of future
fracture risk, as well as other complications [20, 22, 23]. In
all subjects with suspected polyostotic disease, baseline
overnight fasting phosphate levels should be checked. In
case of use of phosphate supplements, serum phosphate
should be measured whilst the patient is off supplements
for at least a day. Values should be related to age specific
reference ranges. Phosphate homeostasis is ideally assessed
in the fasting state by concomitantly collecting serum phos-
phate and creatinine and second void urine phosphate and
creatinine. This will enable calculation of the tubular re-
absorption of phosphate (TmP/GFR) and calculated values
should again be related to age-related reference ranges
[http://members.iinet.net.au/~bill/java/tmp_gfr.html].
It is important to exclude other causes of renal phos-
phate wasting such as hyperparathyroidism and renal
tubular acidosis. This can usually be done through his-
tory, examination and biochemical assessment e.g. dip-
stick urinalysis for glycosuria, measurement of serum
bicarbonate and urinary amino acids. It should be noted
that hypophosphataemia may be episodic and assessment
may need to be repeated if skeletal symptoms change
and during linear growth. If serum FGF-23 is to be mea-
sured the blood sample should be collected at least 7
days off phosphate/ vitamin D supplements, using an
accredited assay/ laboratory if available.
Total alkaline phosphatase (ALP) is the minimum rec-
ommended biomarker for bone turnover. Other bone
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turnover markers are optional and include bone-specific
ALP (with age related reference ranges), procollagen
Type 1 N-terminal propeptide (PINP), C-terminal telo-
peptide (CTX-I). If these are not available, consider stor-
ing serum at − 20 °C for later analysis.
Skeletal imaging is the investigation of choice to deter-
mine skeletal burden depending on the clinical presentation
[24–26]. All skeletal burden is detectable by age 15 years
and clinically significant lesions by the age of 5 years [24].
To evaluate the extent of FD, whole body imaging using
bone scintigraphy, whole body MR or low-dose 2D/3D
radiography (e.g. EOS), to determine the presence and ex-
tent of skeletal involvement should be considered for all pa-
tients ≥ age 5 years. It should be noted that skull base
lesions are likely to be missed by the EOS. Due to the possi-
bility of false negative results, whole body imaging should
be delayed in asymptomatic children until age 5 [24] and
when the child can tolerate an MRI without general anaes-
thesia. Whole body or targeted skeletal imaging prior to
age 5 should be considered when the benefits of early diag-
nosis outweigh the risks of waiting till the child is older.
Scoring of the skeletal burden should be performed using
the Collins’ validated method [25].
Areas of clinically significant axial and appendicular
FD identified on bone scintigraphy should be imaged
with conventional radiographs in two planes of the
whole bone. A localized fine cut CT scan is preferred in
case of clinical evidence of nerve entrapment.
Specific recommendations for spinal FD (Fig. 3c)
Evidence of scoliosis on physical examination should be
confirmed with conventional radiographs. Once estab-
lished, progression of scoliosis should be assessed with
regular, periodic radiographs and pulmonary function
testing. The periodicity of these examinations should be
adjusted based on the severity and rate of progression,
or lack thereof, in a given individual. Early consultation
with spinal team and therapists is recommended and
surgical fixation should be considered if Cobb angle is
above 30 degrees depending on the rate of progression
and location of the curve. [18, 27, 28].
Craniofacial FD (Flow chart Craniofacial FD)
The aim of staging cranio-facial lesions is to define and rec-
ord the extent, distribution and impact of FD in the cranio-
facial skeleton. Following a history and physical examination
the following tests are recommended where clinically rele-
vant: objective assessment of facial asymmetry using clinical
photography and 3D photography and assessment of psy-
chological impact including using the Craniofacial Experi-
ence Index [29]. Radiological assessment includes standard
radiological facial and orthognathic series and fine cut CT 1
mm or less slice thickness. If craniofacial lesions are adjacent
to relevant structures or nerve pathways, referrals should be
considered to the following specialties: craniofacial surgery,
plastic surgery, ophthalmology, ENT & audiology, maxillo-
facial surgery and neurosurgery. A referral to a specialised
craniofacial service should be considered if there is evidence
of nerve impairment of functional impairment.
Dental FD
In case of dental involvement, panoramic radiographs and
intraoral (periapical and bitewing) radiographs will pro-
vide assessment of both arches, as well as adjacent ana-
tomic structures including maxillary sinuses, nasal cavity,
mental foramina and mandibular canals. In addition, use-
ful information will be provided regarding the presence of
carious lesions, periodontal disease, or periapical disease,
all important risk factors for osteonecrosis of the jaw
(ONJ). More advanced imaging techniques include the
use of cone beam computerized tomography (CBCT)
assessing cortical and cancellous architecture with lower
radiation exposure, magnetic resonance imaging (MRI),
99mTc-methylene diphosphonate bone scintigraphy, and
positron emission tomography, (PET).
Extra skeletal system
Endocrine system
Ovarian assessment (See Additional file 4: Flowchart
Endocrine management: Gonadal Evaluation in Girls)
A targeted history and physical examination including
history of breast development, vaginal bleeding and/or
signs of estrogenization (e.g. below age 8 years), ovarian
cysts (Fig. 2a), and irregular menses as defined as menstrual
cycles that are shorter than 21 days or longer than 35 days).
All children should have a review of their growth
curve for linear growth acceleration or deceleration and
a standardised bone age examination [30]. If symptom-
atic, girls should have a random blood FSH, LH, estra-
diol and pelvic ultrasound.
Testicular assessment (See Additional file 4: Flowchart
Endocrine management: Gonadal Evaluation in Boys
and Men)
A targeted history including history of pubertal devel-
opment, and physical examination including Tanner sta-
ging including testicular volume [31, 32]. All males
should have a testicular ultrasound at baseline (Fig. 2b)
and after age 5 to characterise subclinical involvement
consistent with MAS. If symptomatic, boys should have
measurements of FSH, LH and free testosterone.
Thyroid assessment (See Additional file 4: Flowchart
Endocrine management: Thyroid Evaluation)
All patients should have a targeted history and physical
examination, measurement of TSH, free T4 & total or free
T3 and thyroid ultrasound to characterise subclinical
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involvement consistent with MAS (Fig. 2c) [33, 34]. Of
note, in FD/MAS, hyperthyroidism is a T3 driven disease
due to increased deiodinase activity [33] so that measure-
ment of T3/T4 ratios is helpful, with a ratio of > 20 being
indicative of disease.
Pituitary assessment (See Additional file 4: Flowchart
Endocrine management: Growth Hormone Excess
Evaluation)
All patients should have a targeted history and phys-
ical examination including height measurement and
comparison with mid-parental height [35, 36]. All chil-
dren should have a review of their growth curve in rela-
tion to age and stage of pubertal development and head
circumference SDS. Evaluation of growth velocity may
be confounded by bone disease and/or additional endo-
crinopathies. All children should have their bone age
evaluated, with determination of predicted adult height
and comparison with Tanner stage and mid-parental
height (e.g. Bayley N & Pinneau SR [37]. Evaluation of
bone age may be confounded by bone disease.
All patients should have a random blood test for IGF-1,
growth hormone (GH) and prolactin measurements. In chil-
dren biochemical testing, especially of serum GH / IGF-1,
may be misleading in the presence of precocious (or normal)
puberty as likely to be well outside the normal age-related
range. If there is a laboratory abnormality or clinical concern
regarding GH-excess, the recommendation is to investigate
further by measuring IGF-1. Such cases may require a glu-
cose tolerance test and/or overnight growth hormone sam-
pling to confirm the diagnosis. Pituitary MRI is indicated in
case of abnormal biochemistry (Fig. 2d), although a normal
pituitary MRI does not rule out the possibility of GH excess
as the affected tissue may not be detectable by MRI [36].
Patients with endocrinopathies should comply with
additional disease-specific screening programmes as per
published guidelines, e.g. acromegaly and screening for
colonic neoplasia [38].
Adrenal assessment (See Additional file 4: Flowchart
Endocrine management: Adrenal Evaluation (children))
Hypercortisolism presents exclusively in the first year of
life and may spontaneously resolve [39, 40]. A targeted
history and physical examination should be performed, to
include a history of infantile illness, developmental delay,
poor linear growth with excessive weight gain. In case of
clinical suspicion of current hypercortisolism, 24-h urinary
free cortisol, low dose dexamethasone suppression test, di-
urnal cortisol and adrenal CT should be performed. It is
of note that adrenal involvement may present as adrenal
insufficiency in later life reflecting previous (resolved)
hypercortisolism. The ACTH stimulation test should be
performed in all patients with a known or suspected his-
tory of neonatal hypercortisolism.
Dermatological lesions (Fig. 1)
A physical examination should be performed in all pa-
tients for typical café-au-lait macules (any size and dark-
ness with characteristic jagged borders (Coast of Maine)
[41, 42] Figure. The distribution typically respects the
midline of the body). In adults, brown macular lesions
may develop on the lips. Extra care should be taken to
identify lesions in patients with darker skins.
Evaluation of quality of life in FD/MAS
The evaluation of quality of life in patients with FD/
MAS should be performed with language specific ver-
sions of the EQ5D-5 L [43] and SF 36 [44] in adults and
the PEDS-QL [45] in children. Additional measures of
anxiety and depression, e.g. using the Hospital Anxiety
and Depression scale [46] and sleep, e.g. using the
Epworth Sleepiness Scale [47] or Pittsburgh Sleep Qual-
ity Index [48] could be considered. In CFFD assessment
of psychological impact including using the Craniofacial
Experience Index [29] could be considered.
Management of FD/MAS
General measures
Provision of information about the disease
Provision of sufficient information about the disease to
the patient and families is of outmost importance for this
rare disease, which may be associated with debilitating
manifestations, and for which there is no cure and no ap-
proved treatment. The aim is to empower patients and
support them to develop to the best of their abilities.
Patients and their families should be informed of the
non-inherited genetic nature of disease and that while
malignant transformation can very rarely occur, FD/
MAS lesions are almost invariably benign. They should
also be informed that there are no known exposures that
cause FD/MAS. Patients and their families should be
given written information material about FD/ MAS and
informed of the local regional / national / international
patient groups including those based on social media for
additional support. Patients should also be given details
of “Expert” patients and specialist clinical centres / net-
works (e.g. European Reference Networks). Given the
gaps in our knowledge of FD/MAS, research is high pri-
ority and patients should be given information about
local research studies or trials.
Lifestyle advice Advice should be given to optimize life-
style factors which are associated with optimal bone
health. Patients should be advised to achieve appropriate
dietary calcium intake per age and achieve sufficient 25-
OH vitamin D levels as per national guidelines, espe-
cially if pharmacological treatment with anti-resorptives
is contemplated. Smoking cessation, alcohol moderation
to < 3 units/ day and maintaining healthy weight should
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be discussed as required. Appropriate, safe and sufficient
physical exercise to optimize fitness should be recom-
mended with referral for physical therapy as required.
Regular dental examinations should be recommended
according to national guidance including control before
starting medication. Patients should be advised about
optimizing oral health to reduce the risk of oral infec-
tion. Educational materials, occupational advice and infor-
mation on sexual health should be available and, where
appropriate, how to access additional support. Consider-
ation should be made for specific referral to a psychologist
for those with moderate to severe disease, especially in the
presence of significant physical disability and/or craniofa-
cial impact. Referral to a social worker may also be
required.
Exercise and rehabilitation
Advice should be given about appropriate physical exer-
cise, to optimize cardiovascular fitness, and enhance
educational and occupational performance [16, 17]. Re-
habilitation and physical therapy may also be recom-
mended to optimize strength and function, and
attenuate loss of mobility. Orthopaedic review and orth-
oses maybe needed to correct any discrepancy in leg
length (see below)
Specific measures
Management of FGF-23 induced renal phosphate wasting
Patients with FGF-23-mediated hypophosphatemia, es-
pecially children, need to be referred to a metabolic
bone specialist with experience in phosphate wasting
disorders. Interpretation of serum phosphate levels is
based on age. In adults and children, hypophosphatemia
is associated with a higher risk of fractures and should
be treated [20]. Having established that hypophosphate-
mia is due to FD-related FGF-23-induced renal phos-
phate wasting, treatment is similar to other disorders of
FGF-23 excess. A baseline blood sample to measure
PTH, serum adjusted calcium and eGFR, fasting urine
for measurement of urinary calcium/creatinine ratio and
renal ultrasound to establish pre-treatment status re-
garding possible nephrocalcinosis/nephrolithiasis should
be performed. Treatment should be started with an ac-
tive metabolite or analogue of vitamin D. This could be
calcitriol (EU + US) 1μg/day in divided doses or alfacalci-
dol (only EU) 1.5μg/day in a single daily dose in adults
and 15–60 ng/kg/d, divided bid for children. Doses may
be increased as necessary, providing serum and fasting
calcium / creatinine sample or 24-h urinary calcium
measurments are regularly monitored to avoid hypercal-
ciuria and the associated risk of nephrocalcinosis/
nephrolithiasis. The dose of active vitamin D should be
titrated to suppress hyperparathyroidism and maintain
the urinary calcium excretion just below the upper limit
of the normal laboratory reference range. An ultrasound
of the kidneys is recommended in case of persistent
hypercalciuria or every year if the patient is on active
vitamin D and phosphate supplements.
Phosphate supplements should be given in the form of
a drink containing 1 mmol/ml of phosphate divided in
multiple doses throughout the day e.g. 5-10 ml tds for
adults and 1–3 ml/kg body weight qds for children.
Phosphorus supplementation can also be expressed in
mg/kg, especially during paediatric age, with a range
from 15 to 60 mg/kg/day, divided in 4–5 doses. The dose
of phosphate supplement should be titrated to maintain
serum phosphate at the lower end or just below the nor-
mal laboratory reference range for serum phosphate.
Care should be taken to avoid overtreatment. Patients
should be advised of the potential for gastrointestinal
upset and to consider taking a smaller dose more often.
Long-term phosphate supplementation is associated
with chronic stimulation of parathyroid hormone secre-
tion, potentially leading to 4-gland hyperplasia and au-
tonomous hyperparathyroidism precluding the further
use of active metabolites of vitamin D and requiring sur-
gical intervention to remove the hyperplastic glands.
PTH concentrations need to be monitored after one
month of therapy and as frequently thereafter as re-
quired by dose changes and level of PTH while under
treatment with phosphate.
Management of Scoliosis
Patients with scoliosis should be regularly monitored for
progression. Early consultation with spinal team and
therapists is recommended and surgical fixation should
be considered if Cobb angle is greater than 30 degrees,
depending on the rate of progression and location of the
curve [18, 27, 28].
Management of bone pain (See Additional file 3: Flowchart
Management of Bone Pain)
The strategy is to induce symptom remission [22, 49–57].
Key assessment tools for bone pain in FD are outlined
above. The presence of night pain is red flag and the pa-
tient should be evaluated for complications including
imminent fracture, bleeding into a cyst and malignant
transformation. The presence of focal and/or acute onset
pain may also indicate an acute or impending fracture (es-
pecially in a deformed long bone) or an aneurysmal bone
cyst. Mechanical/ weight bearing bone pain can also signal
a stress or impending fracture. The presence of a stress
fracture should trigger consideration for correction of
alignment, and/or consideration for the necessity of a sur-
gical procedure, possibly involving the use of an intrame-
dullary titanium nail or of a custom-made titanium angled
blade plate, to stabilize the bone to prevent an
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uncontrolled fracture. (See Additional file 5: Flowchart
Surgical management of FD of the proximal femur)
Pharmacological management The first step in the
pharmacological management of FD is to ensure supple-
mentation (not correction) of hypophosphatemia if
present (see above), and vitamin D repletion (according
to national guidelines). For analgesics, consider paraceta-
mol/acetaminophen as first line, followed by NSAIDs, if
benefits outweigh cardiovascular, renal and gastro-
intestinal risk. Bone therapies should be tried before
recommending tramadol and other opioids. If neuro-
pathic features such as burning or stabbing pain are
present, consider an atypical analgesic ladder, e.g. ami-
triptyline, gabapentin, pregabalin and duloxetine. Of
note, these medications are proposed by analogy with
other painful diseases, but no specific trial has been con-
ducted in FD. If pain management becomes complex,
consider pain specialist review. Consider cognitive ther-
apies and sleep hygiene interventions as used for chronic
pain. Referral for physical therapy is recommended to
optimize function and reduce pain.
Bisphosphonates are proposed for persistent, moderate
to severe pain as defined by VAS score of > 3/10. It re-
mains unclear whether bisphosphonates reduce FD lesion
size or progression in children or adults. Their ability to
increase local bone density or preventing complications
has not been established. Prior to their use, ensure that
the patient is normo-calcaemic, has an adequate dietary
calcium intake and an adequate 25OH vitamin D level (ac-
cording to national guidelines) and that the creatinine
clearance is ≥35ml/min. Importantly, hypophosphatemia
should be corrected as best a possible for least 6months
prior to initiating bisphosphonates. Treatment protocols
for the most commonly used bisphosphonates are shown
in the Table 3. There is no evidence to support use of alen-
dronate or risedronate for treatment of pain in fibrous
dysplasia. High dose alendronate, 40mg daily, does not
improve pain in a controlled trial [53]. Oral bisphospho-
nates, at any dose, are therefore not recommended for the
treatment of bone pain.
Intravenously administered pamidronate and zoledro-
nate can be equally considered (Table 3). The aim of initial
dosing is to establish whether bisphosphonates are effect-
ive in providing pain relief. Several doses may be required
initially to establish whether they are effective in providing
analgesia. Subsequent dosing intervals should be deter-
mined according to need for analgesia and response to
previous doses. In general, one should aim to increase the
interval between doses over time.
Patients and families should be counselled about short
and long-term risks and concerns possibly associated with
the use of bisphosphonates. Consideration should be given
to appropriate monitoring of bone health according to
dose and duration of therapy which may include the
serum measurement of bone turnover markers and bone
density. Dental evaluation is recommended prior to treat-
ment to minimize the risk of osteonecrosis of the jaw.
There have been no reports of atypical femur fractures
despite the high cumulative doses used long-term in some
of the reported large case series [52].
If there is an inadequate clinical improvement, as mea-
sured by no or insufficient change in pain score, other
non-bone causes of pain should be excluded before
switching to the other parenteral bisphosphonate. If
there is still no improvement in pain, then do not con-
tinue with bisphosphonate therapy and review other
causes of pain and consider other analgesic strategies.
Evidence for the dosage, efficacy and safety of other
anti-resorptive agents such as denosumab is currently
scarce and the use of this agent is not recommended
outside specialist centres, preferably in the context of a
clinical study or trial. The main concern raised so far
with the use of this agent in FD is the apparent in-
creased risk of significant hypercalcaemia following ces-
sation of therapy in children [58] and rebound increase
in fracture rate in adults treated with denosumab for
osteoporosis when therapy is discontinued [59].
Management of Mazabraud syndrome
More often than not myxomas of Mazabraud’s syndrome
are asymptomatic, and require no intervention. However,
surgical excision is recommended if they become painful,.
There may be a local recurrence risk of up to 25%.
Follow-up scanning with MRI is dependent on clinical
symptoms. Longer term surveillance and testing for other
extra-skeletal manifestations is recommended in polyosto-
tic FD and in the presence of other features of MAS.
Management of Endocrinopathies
Ovarian pathology [52–57] (See Additional file 4:
Flowchart Endocrine: Management of precocious pu-
berty in girls)
In general, ovarian surgery for cysts should be avoided,
as disease is usually bilateral. Ovariectomy should only
be performed when there is a risk of torsion and after
expert consensus. Patients should be informed that the
risk of torsion is small.
Treatment for precocious puberty is indicated if bone
age is advanced and there is frequent bleeding. Psycho-
logical distress and the patient’s age need to be taken
into account as the height outcome is only improved in
those <6ys at onset i.e. the very young group. First line
therapy is letrozole, with tamoxifen or fulvestrant as sec-
ond line or adjuvants. Patients should be monitored for
central puberty and the need to add a gonadotropin-
releasing hormone analogue (GnRHa), e.g. leuprolide.
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Adult women should be monitored for dysfunctional
uterine bleeding. For contraception and HRT it may be
prudent to avoid additional estrogenic compounds to
avoid a possible increase in the risk for breast cancer,
since patients with MAS may be at an increased risk of
estrogen positive breast cancer [60], and patients with
precocious puberty have both longer exposure as well as
continued intermittent autonomous production of high
levels of estrogen up until the menopause.
Testicular pathology [31] (See Additional file 4: Flow-
chart Endocrine: Management of precocious puberty in
boys & men)
In general, surgery should be avoided. Structural le-
sions are rarely of clinical significance. Treatment for
precocious puberty is indicated in case of an associated
elevated serum testosterone and/or bone age advance-
ment. Combination of testosterone receptor blocker and
aromatase inhibitor are needed as well as monitoring for
central precious puberty, in which case GnRHa may
need to be added.
Testicular lesions should be examined annually and
males informed to perform self-examinations. Annual
ultrasonography is indicated for palpable lesions or for le-
sions causing an overall increase in the size of the testes
(relative to other testis or stage of puberty).). In adulthood
no routine ultrasounds are advised, unless lesions are chan-
ging. Consider biopsy for lesions that are changing in size.
Thyroid pathology [33, 34, 61] (See Additional file 4:
Flowchart Endocrine: Management of hyperthyroidism)
In the short-term, carbimazole or methimazole are rec-
ommended for hyperthyroidism, whereas thyroidectomy
or radio-ablation are recommended for long standing
hyperthyroidism of more than 5 years.. Patients can be
treated with I-131 but considering the evaluation of
thyroid nodules one should perform full evaluation of the
nodule before treating with I-131.
Annual long-term monitoring is advised due to the
possibility of regrowth. For, children aged less than 10
years with an abnormal US and normal thyroid function
tests (TFTs), physical examination, growth velocity, and
TFT’s should be monitored every 6 to 12month. In case
lesions are found, follow up of patients with FD/MAS-
related thyroid disease should be performed according
to current (inter) national guidelines [62–64].
Growth hormone excess [36, 65–69] (See Additional
file 4: Flowchart Endocrine: Management of growth
hormone excess)
Somatostatin analogues are first line therapies with
second line options including pegvisomant, alone or in
combination with octreotide or lanreotide at the discre-
tion of the treating physician. Pituitary surgery is recom-
mended for patients resistant to medical therapy. Total
hypophysectomy is required as the whole gland is usu-
ally involved and removing just the adenoma is not
enough to control the excess production of growth hor-
mone. Surgery is almost universally complicated by co-
existent craniofacial FD, and so always challenging. Max-
imal medical therapy is standard of care, and pituitary
radiation should be a final recourse due to the risk of
malignant transformation of skull base FD [36, 70]. The
treatment goals are to achieve an IGF-1 Z-score between
− 2 and + 1. Treatment should be monitored by annual
growth velocity, head circumference, and IGF-1 in all
growing children. Assessment of additional pituitary
hormone deficiencies is recommended after hypophysec-
tomy and/or radiation therapy.
Adrenal pathology [39, 40] (See Additional file 4: Flow-
chart Endocrine: Management of hypercorticolism)
Table 3 Example of intravenous bisphosphonate regimens used for the management of bone pain in patients with fibrous
dysplasia / McCune Albright Syndrome
Pamidronate Zoledronate
Loading Dose Stop if Comments Loading Dose Stop if Comments
Paediatrica 1 mg/kg × 2 on
consecutive days up
to a total of 90 mg.
If no response,
consider repeat at
week 8.
No
response
after 2
cycles
Consider use of 20–30 ng/kg/
day calcitriol or 30–50 ng/kg/
day alfacalcidol up to 1 mcg/
day and calcium supplements
for 4 days after first injection to
maintain calcium homeostasis
especially in those with high
disease burden.
0.025mg/kg. If no
response, 0.025 mg/
kg at week 8. If still
no response, 0.05
mg/kg at week 24
No response
after 3 doses
Consider use of 20–30 ng/kg/
day calcitriol or 30–50 ng/kg/
day alfacalcidol up to 1 mcg/
day and calcium supplements
for 4 days after first injection to
maintain calcium homeostasis
especially in those with high
disease burden
Adult 90 mg ×2
consecutive days
every 6 months
No
response
after 2
cycles
Up to 5 mg
monthly (switch to
maintenance dose
when achieve
response)
No
improvement
in pain after 3
doses
Legend: a Dosing examples are intended for children age 3 and above. If pain management is needed for a child under age 3, recommend consulting with a
paediatric metabolic bone specialist. bMonthly zoledronate is usually reserved for severe cases with a very high skeletal burden. Most cases require annual or
bi-annual therapy
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Metyrapone is the preferred first-line agent with etomi-
date for critically ill patients. Other options include mito-
tane and ketoconazole. Ketoconazole should be used with
caution as it is frequently associated with hepatic toxicity.
However, bilateral adrenalectomy is usually required. Uni-
lateral adrenalectomy may be considered in stable patients
who have the appearance of unilateral disease. Of note,
spontaneous resolution occurs in up to 1/3 of patients. In
stable patients, adrenalectomy could be deferred with
close monitoring for resolution. The benefits and risks of
medical therapy should be balanced with the potential de-
velopmental risks of continued hypercortisolism. Assess-
ment of adrenal insufficiency is recommended after
resolution of hypercortisolism.
Management of other extraskeletal manifestations of FD/
MAS
Haematological manifestations [71] Platelet function
activation testing should be performed if there is a
history of bleeding. If abnormal, this can be corrected
pre-operatively by platelet transfusion.
Gastrointestinal manifestations [72–75] Gastrointes-
tinal polyps and hepatobiliary neoplasms have been re-
ported in FD, although their clinical significance is
unclear. Pancreatic disease, including intraductal papil-
lary mucinous neoplasms, have also been described and
a single case of malignant transformation has been re-
ported. Pancreatic pathology may be associated with
acute or chronic pancreatitis and serum amylase should
be measured if there is history of abdominal pain. It is
recommended that all patients are evaluated for gastro-
intestinal symptoms and imaging considered for symp-
tomatic patients and those with a history of pancreatitis.
Malignancies [4, 31, 61, 76–79] There is a likely small
increased baseline risk of developing malignancies in
mutation-bearing tissue as well as in lesions with high
turnover. Patients should be encouraged to be compliant
with existing cancer screening programmes for the general
population such as screening for breast and prostate can-
cer, as an increased risk for these malignancies has been
observed in patients with FD. Patients with endocrinopa-
thies should comply with additional disease-specific
screening programmes as per published guidelines, e.g. ac-
romegaly and screening for colonic neoplasia [38].
Patients should be advised to avoid additional risk
factors (excessive radiation exposure, smoking, exces-
sive alcohol, etc.)
Surgical management of FD/MAS
Management of orthopaedic issues requires working within
a multidisciplinary team to ensure optimal phosphate status
and exclusion of endocrine abnormalities that exacerbate
skeletal disease (e.g. GH excess and T3 thyrotoxicosis). Re-
view by a specialist orthopaedic surgeon is needed for frac-
ture, potential mechanical/ tumour bone pain or limb
deformity. Limb deformity requires early assessment for
prophylactic surgery to prevent worsening deformity, pain
and fracture [80]. Leg length discrepancy requires assess-
ment for the need for orthotics and corrective surgery.
The presence of joint-based pain may require referral
for physiotherapy, analgesics, osteotomy (especially if
there is deformity) and/or arthroplasty. Whereas curettage
may be effective in a very low volume bone lesion, curet-
tage filled with bone (auto or allogenic) grafts is not rec-
ommended as it is ineffective and may be associated with
complications. In general, external fixation is only used for
temporary correction and/or fixation, while waiting for a
more definitive custom-made printed implant. Preferred
internal fixation is with a titanium intramedullary nail,
bridging the involved bone where possible. In special cir-
cumstances plate fixation can be considered. Internal fix-
ation using conventional titanium plates or custom-made
titanium plates by bridging the involved bone is another
option. There appears to be a higher rate of fracture after
steel plating vs. titanium plating and this may be related
to the better elastic modulus of titanium compared with
steel. The stabilization procedure is often facilitated by
performing a correction osteotomy. Allogeneic cortical
strut grafting (tibia or fibula) has been used for bridging
the involved bone, for small FD lesions, but is not recom-
mended after incomplete or complete fractures.
Given that FD lesions are vascular, blood loss can be sig-
nificant and staged procedures are therefore recom-
mended if multiple surgeries are planned in order to
minimize the need for transfusions. Consider interven-
tional radiological control with either embolization or bal-
loon catheter for very high flow lesions. There is so far no
evidence for added value of using of bisphosphonates to
decrease vascularity of FD lesions pre-operatively although
this warrants testing formally in future studies. For chil-
dren or severely affected adults, active follow-up is needed
in the medium and long term as the deformity may recur
and require further surgery. Rehabilitation including
physiotherapy, hydrotherapy and mobility aids should be
available as needed after surgery.
Also see: (See Additional file 5: Flowchart Surgical
management of FD of the proximal femur)
Management of Craniofacial FD (CFFD) [51, 81–86] (See
Additional file 6: Flowchart: Management of CFFD)
FD of the craniofacial skeleton is variable in its behaviour
and the multidisciplinary team caring for patients with
CFFD needs its combined expertise to cater for all treat-
ment options. Any planned surgical treatment should be
carefully coordinated with other specialists involved in the
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patient’s care. Working within a multidisciplinary team,
thus ensures among other aspects of management, optimal
phosphate status, adequate vitamin D and preoperative cor-
rection of endocrine abnormalities, such as GH excess and
T3 thyrotoxicosis, that may exacerbate skeletal disease. The
balance of risks and benefits of extensive resection and/or
reconstruction needs to be carefully outlined in great detail
in patients with CFFD. Active watch and wait policies are
often the preferred management strategy, as long-term out-
comes in terms of regrowth and pain are very variable and
generally poorly predictable.
If CFFD is identified at baseline or at subsequent moni-
toring evaluations, the patient should be referred for a for-
mal assessment to a craniofacial service with experience
in the care of patients with CFFD. The goals of treatment
are: a) Prevention of functional loss – especially hearing
and vision; b) Arrest or reduction of physical disfigure-
ment; c) Prevention of secondary deformity; d) Minimisa-
tion of long-term morbidity from CFFD and its treatment.
The structure of the individualised package of care of
CFFD is based on the extent of craniofacial involvement
and on the following concepts. If possible, care is to be
provided locally, but any decisions regarding surgical
intervention should be taken by a multidisciplinary spe-
cialised team including physicians and surgeons with ex-
perience in managing CFFD. Scheduling of periodic
evaluations should be organised by the central coordin-
ating CF team with CFFD patients being reviewed at
least annually or more frequently depending on the ex-
tent of their disease and risk of complications. Baseline
and periodic CT scans of the head should be performed
in children, usually every 2 years or less frequently based
on the localisation and severity of the lesion(s). Regular
imaging is not indicated In adults, and timing of the
scans should be based on symptoms, at most every 5
years in those without symptoms.
Although the primary aim of treatment should always
be to preserve function, treatment of primary deformity
and prevention of secondary deformity are also import-
ant. Advanced imaging techniques and 3-dimensional
analysis of scans together with virtual surgical planning
and computer-aided manufacturing and design of
patient-specific implants should be regarded as the
standard of care in surgery of FD of the craniofacial skel-
eton. Simple curettage is not recommended as it is inef-
fective and may increase the risk of complications.
Specific CFFD management recommendations Le-
sions of the cranial vault usually present as a mass, asym-
metry or other form of physical deformity and treatment
options include: burring of the lesion to reduce bulk and
achieve symmetry; subtotal excision and reconstruction;
complete excision of the lesion and reconstruction of the
calvarial defect.
Lesions of the skull base should be monitored by peri-
odic evaluation by the craniofacial team. Any evidence of
functional embarrassment of the structures exiting the
skull base should prompt a review by a skull base surgeon.
Surgery should be avoided in the absence of functional
deficits. An assessment of hearing should be performed
annually in all patients with skull base disease.
Lesions of the frontal bone usually present as a physical
deformity or asymmetry. These lesions often alter orbital
morphology, affect the position of the globe and can cause
significant deformity. Although diplopia is not a common
symptom of CFFD, surgical intervention may be associ-
ated with this disabling complication. Pre-operative oph-
thalmological evaluation is essential to establish the
likelihood of post-operative diplopia and the fusion range.
Surgical options include: burring of the lesion to reduce
bulk and achieve symmetry; subtotal excision and recon-
struction; excision of CFFD lesion and reconstruction of
the fronto-orbital defect and correction of the globe’s pos-
ition. Prophylactic optic nerve decompression is not rec-
ommended. Proven visual deterioration with sequential
ophthalmological evaluation warrants an urgent evalu-
ation by a craniofacial surgeon with experience in the
management of fibrous dysplasia.
Lesions of the naso-ethmoid region can affect the air-
way and globe of the eye’s position. An ENT evaluation
is recommended in addition to a detailed ophthalmo-
logical evaluation. Treatment strategies are aimed at: re-
ducing airway obstruction; correcting globe position and
visual function and correcting physical deformity. Surgi-
cal options include: subtotal excision via limited access/
endo-nasal approach and radical excision with recon-
struction of the skull base and orbits.
Maxillary lesions affect both orbital morphology and
contents as well as dental occlusion. Surgical strat-
egies include: preserving occlusal function and denti-
tion (including tooth buds as well as erupted teeth);
correcting globe position and visual function; redu-
cing secondary deformity and using stealth incisions
to minimise surgical morbidity. Surgical options in-
clude: burring of lesions to achieve symmetry and re-
duce bulk; subtotal excision and reconstruction of
orbital floor and maxilla as required; radical excision
and reconstruction of the orbit and maxillary arch to
enable dental rehabilitation.
Mandibular lesions: Although CFFD of this site often
presents with a mass in the lower border of the man-
dible, disease progression will lead to dysfunction. Like
the maxilla, surgical strategies should be directed at: pre-
serving occlusal function and dentition (including tooth
buds as well as erupted teeth), reducing secondary de-
formity; and using stealth incisions to minimise surgical
morbidity. Surgical options include: burring of lesions
to achieve symmetry and reduce bulk; subtotal
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mandibular excision and reconstruction; and radical
excision and reconstruction.
Oral and dental management in FD/MAS [84, 87–89]
Patients with FD, including CFFD, do not require special
dental management and are able to undergo routine den-
tal and orthodontic treatments without exacerbating their
craniofacial lesions. However, malocclusion, dental crowd-
ing and smoking contribute to poorer oral hygiene [82].
Dental anomalies such as oligodontia, enamel hypopla-
sia, dentin dysplasia, taurodontic pulp, odontoma, tooth
displacement, malocclusion, and high caries activity have
been reported in 28% of patients with craniofacial FD.
For this reason, all patients with CFFD should be care-
fully monitored for the appearance of these dental
anomalies during growth
The risk of ONJ is discussed in the section on oral
bisphosphonates. Management of ONJ is based on the
stage of the disease, size of the lesions, and the presence
of contributing drug therapy and comorbidity [88]. An
important preventative strategy includes maintenance of
good oral hygiene, elimination or stabilization of oral
disease prior to initiation of treatment with an anti-
resorptive agent and as far as possible avoidance of inva-
sive dental procedures during treatment. Frequent re-
calls may be required for scaling and root planning to
control dental plaque accumulation. Orthodontic tooth
movement tends to be rapid in jaws with fibrous dyspla-
sia and relapse is more common as teeth tend to return
to their original position after removal of orthodontic
appliances due to poor quality of FD bone.
Orthodontic treatment must be preceded by radio-
logical evaluation to detect remodeled areas to inform
orthodontic therapy. Functional removable appliance
therapy should be preferred whenever possible. Fixed ap-
pliance therapy requires the maintenance of excellent
oral hygiene conditions. In the vast majority of cases of
craniofacial FD, orthognatic surgery is not needed, and
observation is the correct approach. Indications for sur-
gery include documented progressive, severe pain, or se-
vere disfigurement. Results have been shown to be stable
with no recurrence after surgery in adults.
Orthognatic surgery helps to restore stable occlusion
and good facial aesthetics, but should be avoided in
growing patients as in young patients as abnormal facial
growth has been described in young patients operated
during the active phase of growth.
Conclusion
These best practice guidelines have been developed by
an international collaboration between multiple clinical
specialities, patients and patient advocacy groups, using
the best evidence available. The FD/MAS guidelines are
intended to improve the clinical care of patients across
the world by addressing diagnosis, staging, treatment
and monitoring aspects of their care given the potential
serious risks to patient outcomes with late diagnosis
[90]. The provision of a Patient Checklist (See Add-
itional file 1: Fibrous Dysplasia and McCune-Albright
Syndrome: A Checklist of P atients and Doctors) is
aimed at informing and empowering patients to seek ex-
cellence of healthcare for their disease. Describing stan-
dards across the clinical care pathway enables clinical
services to be audited, helps in the identification of areas
of the patient pathway that require service improvement
and facilitates cross-border sharing of best clinical prac-
tice between clinical services in different countries.
These guidelines have additionally highlighted important
gaps in our knowledge about FD/MAS and raise the im-
portance of implementing international registries and co-
hort studies with active collaboration of patients and
families. Currently, such initiatives include the Fibrous Dys-
plasia Foundation Registry (https://fibrousdysplasia.org),
RUDY study (www.rudystudy.org) [91], James Lind Alliance
Priority Setting Partnership for Rare Musculoskeletal Dis-
eases in Adulthood (http://www.jla.nihr.ac.uk/) and Euro-
pean Reference Networks for rare bone (http://ernbond.
eu/) and endocrine diseases (https://endo-ern.eu). The FD/
MAS consortium commits to developing an audit tool of
key performance and experience measures to an inter-
national audit of practice and to reviewing these recom-
mendations at least every 5 years to reflect new evidence in
FD/MAS natural history and management.
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